ERBB2 and breast carcinoma: Finally, metastasis-free survival was reduced in patients with ERBB2+/ER+ breast cancer in which TOM1L1 was also amplified compared with those without TOM1L1 amplification (patients selected from our previous work26) (Fig. 1e).